San Francisco · Pre-Seed–Late Stage · 13 people tracked
Also known as AWESOME ENABLERS, L.L.C. · MBC FII MANAGEMENT, LLC · Mission Wealth Management, Lp
Find your way into Mission Bay Capital
10,983 people in our graph share verified history with the Mission Bay Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Mission Bay Capital aims to help entrepreneurial scientists turn ideas into successful companies, viewing startups as an efficient engine for positive change. It provides critical early-stage capital to prove out technologies at a point when other investors are hesitant. Through its MBC BioLabs incubator, the firm offers state-of-the-art laboratory facilities so startups can begin experiments immediately, helping founders operate efficiently. It further supports portfolio growth through a network of advisors, industry partners, university colleagues, and co-investors. The firm concentrates on science-driven ventures tackling oversized problems including chronic diseases and global environmental challenges.
Source: firm website, verified Sep 1, 2026.
Team · 13 people
from the firm's website & curated & public directories
Founder mafia
2 people who came through Mission Bay Capital went on to found or lead other companies.
What they invest in
from 25 of 33 portfolio companiesBiotech ×21Medical Devices ×12Healthtech ×10Deep Tech ×6AI & Machine Learning ×2Longevity ×2Creator Economy ×1Digital Health ×1
HQs:United States×21
Who they back
founder profiles across 15 portfolio companiesFounding team size:solo founder×72 founders×23 founders×34+ founders×3
Where their founders studiedfrom 12 founders with education data
Harvard University ×4University of California, Berkeley ×2
Where their founders worked beforefrom 13 founders with career history
Stanford University ×2
Investments · 33 tracked
founders shown can be your intro pathBy year:2023 · 12016 · 12015 · 13 dated
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in
BoardCarl Gordon(Director)Terry McGuire(Director)in
Co-investorsForesite CapitalMission BiocapitalMRL Ventures FundSV Health InvestorsPolaris Partners
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.
BiotechMedical DevicesBerkeley, US
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)inMartin Jinek(Co-founder)Andrew May(Executive Officer)
BoardJenny Rooke(Director)Robert Weisskoff(Director)in
Co-investorsAliment CapitalAvego BioScience CapitalF-Prime CapitalIA Seed VenturesMission BiocapitalPontifax AgTech+2 more
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Director & Chief Scientific Advisor)inCam Gallagher(President & Chief Executive Officer)inJohn Maroney(Executive Officer, Director)in
BoardZachary Collins(Executive Officer)inSteve Tregay(Director)inAnnie Mitsak(Director)in
Co-investorsCure VenturesMission Biocapital
Avvio Medical develops Microbubble SonoLithotripsy, a minimally invasive outpatient procedure that uses low-intensity ultrasound to break down ureteral stones without requiring general anesthesia or stents.
Deep TechHealthtechMedical DevicesSan Francisco, US
Co-investorsBaruch Future VenturesBerkeley CatalystMission Biocapital
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Founder)in
Co-investorsEmles Venture PartnersGoAhead VenturesMission BiocapitalRA CapitalY CombinatorAlexandria+3 more
BiotechRedwood City, US
William Robinson(Director)Lawrence Steinman(Director)Tito Serafini(Executive Officer, Director)
BoardBrian Atwood(Director)Franklin Berger(Director)
Co-investorsAisling CapitalEcoR1 CapitalEvolution VC PartnersMission Biocapital
Co-investorsMission Biocapital
Bolt Threads was a manufacturer of biomaterials for personal care formulations.
BiotechNew MaterialsFoxboro, US
Ethan Mirsky(Executive Officer)David Breslauer(Executive Officer, Director)Daniel Widmaier(Executive Officer, Director)
BoardJerry Fiddler(Director)Steven Vassallo(Director)inJim Kim(Director)
Co-investorsMission Biocapital8VCBaillie GiffordEast West Capital LimitedFidelity InvestmentsFoundation Capital+2 more
Co-investorsMission BiocapitalLongwood Fund
BiotechLafayette, US
Peter Emtage(Executive Officer)Greg Giotta(Executive Officer)Brian Atwood(Executive Officer, Director, Promoter)
BoardFred Cohen(Executive Officer, Director, Promoter)Brook Byers(Director)inArie Belldegrun(Director)
Co-investorsKleiner PerkinsOUP (Osage University Partners)
HealthtechHayward, US
GUY DIPIERRO(Director)ALAN LEVY, PH.D.(Executive Officer, Director)ANTHONY RIMAC(Executive Officer)ALAN LEVY(Executive Officer, Director)
BoardELIZABETH ROCKETT(Director)WENDE HUTTON(Director)in
Co-investorsEmergent Medical Partners, LLPFountain Healthcare PartnersKaiser Permanente Ventures5AM VenturesCanaan PartnersGE Ventures
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)inWalter H. Moos(Director)
Co-investorsBerkeley CatalystLifeforce CapitalMission BiocapitalNextech InvestPandect BioventuresThe Column Group+1 more
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalMission BiocapitalOlive Tree CapitalSR One Capital ManagementTaiho Ventures, LLC+1 more
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Co-investorsAstellas Venture Management LLCMission BiocapitalOUP (Osage University Partners)Pfizer Venture InvestmentsUS Venture PartnersSofinnova Ventures
Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk.
BiotechHealthtechMedical DevicesSan Francisco, US
Brian Shoichet(Director)Douglas Crawford, Ph.D.(CEO)Don Gehlert, Ph.D.(Head of Biology)in
BoardDouglas Crawford(Executive Officer, Director)in
Co-investorsMenlo VenturesMission BiocapitalKleiner Perkins
BiotechDeep TechHardware
Co-investorsClaremont Creek VenturesMission BiocapitalSignet Healthcare Partners
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
Biotech
Steven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesMission BiocapitalRemiges Ventures, Inc.RiverVest Venture PartnersSanderling VenturesSanofi Ventures
Invenio develops rapid on-site tissue imaging systems combined with AI to improve cancer patient care.
AI & Machine LearningBiotechDeep TechMedical DevicesSanta Clara, US
Jay Trautman(President & CEO, Co-Founder)inChris Freudiger(Chief Technology Officer, Co-Founder)inChristian Freudiger(Director)inXiaoliang Xie(Director)
BoardDoug Crawford(Director)in
Co-investorsBerkeley CatalystMission Biocapital
Kit provides email marketing and commerce tools for creators and independent businesses to reach audiences and monetize their work through newsletters and storefronts.
Creator EconomyMarketing TechSaaS
Nathan Barry(Founder + CEO)in
Co-investorsAUTHENTIC VENTURESBrighter CapitalExpaMission BiocapitalWAGMI VenturesOceans Ventures+1 more
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BiotechDeep TechMedical DevicesBrisbane, US
Jennifer Doudna(Founder)inTrevor Martin(Co-founder, Chief Executive Officer)inJanice Chen(Co-founder, Chief Scientific Officer & President, Research)inLucas Harrington(Co-founder)inAshley Tehranchi(Executive Officer, Director)in
BoardUrshit Parikh(Director)
Co-investors8VCBerkeley FrontierCALIFORNIA INNOVATIONDecheng CapitalForesite CapitalMayfield Fund+9 more
MPM Capital is a venture capital and life sciences investment firm that backs companies in biotech, therapeutics, and healthcare innovation, with a focus on translating scientific research into transformative medicines and treating severe diseases.
Biotech
Ansbert Gadicke(Chairman)inChris Bardon(Managing Partner)in
Berkeley, US
Co-investorsAutodesk FoundationAVA AngelsBerkeley SkyDeck FundCRV (Charles River Ventures)Melbourne Accelerator Program (MAP)Moonhill Capital+1 more
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)in
Co-investorsMission BiocapitalSofinnova PartnersDementia Discovery Fund
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)Joshua Resnick, M.D.(Director)
BoardMichael Powell(Director)
Co-investorsMission BiocapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova VenturesSofinnova Venture Partners
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)
BoardPETER THOMPSON(Director)SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsAccess BiotechnologyMission BiocapitalSofinnova VenturesNew Leaf Venture PartnersOrbiMedSamsara BioCapital
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health Investors+6 more
Vedere Bio develops optogenetics-based gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA), using proprietary AAV vectors for intravitreal administration to restore vision in visually impaired patients globally.
BiotechDeep TechMedical DevicesCambridge, US
Co-investorsMission Biocapital
BiotechSan Francisco, US
Leah Makley(Executive Officer, Director)Ed Hurwitz(Executive Officer, Director)Jason E. Gestwicki(Director)
BoardDouglas Crawford(Director)Emmett T. Cunningham, Jr.(Director)Mark Blumenkranz, M.D.(Director)
Co-investorsBiotechnology Value FundRed Tree VentureThe Rise Fund
Co-investorsPfizer Venture Investments
Exits · 3
IPOs and acquisitions across the tracked portfolioAlectorNASDAQ: ALECCaribou BiosciencesNASDAQ: CRBUFluxionacq. by Cell Microsystems
Portfolio news
latest coverage across their companies
Alector · dailypolitical.com · Jul 17, 2026
Epiodyne · aventure.vc · Jun 18, 2026
Caribou Biosciences · ad-hoc-news.de · May 19, 2026
Quralis · nasdaqprivatemarket.com · Apr 3, 2026
Alessa Therapeutics · thecompanycheck.com · Mar 17, 2026
Dren Bio · biospace.com · Mar 2, 2026
Fund performance · per public LP disclosures · 2
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Mission Bay Capital IIILPs: The Regents of the University of California | 2018 | — | 21.8% | 2.11x | 0.28x |
| Mission Bay Capital IILPs: The Regents of the University of California, Sobrato Family Foundation | 2015 | — | 14.7% | 2.35x | 0.98x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Mission Bay Capital made?
- Mission Bay Capital has 29 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does Mission Bay Capital invest at?
- Mission Bay Capital invests at the Pre-Seed, Seed, Series A, Late Stage stages.
- What sectors does Mission Bay Capital focus on?
- Mission Bay Capital focuses on Biotech, Climate Tech, Deep Tech, Healthtech, Medical Devices.
- Where is Mission Bay Capital located?
- Mission Bay Capital is headquartered in San Francisco, US.
- Who does Mission Bay Capital co-invest with?
- Mission Bay Capital most often shares deals with Mission Biocapital, Berkeley Catalyst, OUP (Osage University Partners), among 67 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Safar Partners is an early-stage technology investment firm that backs startups spun out of leading research universities, primarily MIT, Harvard, and the University of Rochester.